Labetalol injection patient counseling information

Revision as of 20:20, 5 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Labetalol}} {{CMG}}; {{AE}} {{SS}} ==Patient Counseling Information== As with all drugs with beta-blocking activity, certain advice to patients being treated wit...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Labetalol
LABETALOL tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
LABETALOL injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Labetalol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol HCl is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. While no incident of the abrupt withdrawal phenomenon (exacerbation of angina pectoris) has been reported with labetalol HCl, dosing with labetalol hydrochloride tablets should not be interrupted or discontinued without a physician's advice. Patients being treated with labetalol hydrochloride tabletsshould consult a physician at any signs or symptoms of impending cardiac failure or hepatic dysfunction (seeWARNINGS). Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tabletsis initiated (see ADVERSE REACTIONS). [1]


References

  1. "LABETALOL HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.]". Retrieved 5 February 2014.


Template:WikiDoc Sources